REGISTERED
on 12 Nov 2024
Last Applicant/ Owned by
No. 2727 Jinke Road, Pilot Free Trade Zone 201203 Shanghai
CN
Serial Number
79370455 filed on 02th Mar 2023
Registration Number
7561433 registered on 12th Nov 2024
Correspondent Address
Michael T. Smith
Michael T. Smith Birch Stewart Kolasch & Birch LLP
Beijing Global Trade Center,
Falls Church, VA 22042
United States
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
CAPDRIVE
Scientific research and development; scientific research; technological research, namely, research on the subject of pharmaceuticals; biological research; scientific research in the nature of conducting clinical trials for others; medical research; pharmaceutical research services; research on the subject of pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; structu Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Scientific research and development; scientific research; technological research, namely, research on the subject of pharmaceuticals; biological research; scientific research in the nature of conducting clinical trials for others; medical research; pharmaceutical research services; research on the subject of pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; structural and functional analysis of genomes; biotechnology research; analysis of the mode of action of chemical combinations on animals; research and development services in the field of antibodies; genetic testing for scientific research purposes; biological research and analysis; pharmaceutical drug development services; DNA screening for scientific research purposes; medical research; testing of pharmaceuticals; biomedical research services
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Stem cells for medical purposes; biochemical medicine for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; biological preparations for medical purposes, namely, for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; biological tissue cultures for medical purposes; chemical preparations for medical purposes, namely, for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; chemical preparations for pharmaceutical purposes, namely, for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; chemico-pharmaceutical preparations for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the central nervous system; ophthalmological preparations; pharmaceutical preparations for the treatment of immune system related diseases and disorders; cardiovascular agents for medical purposes; cellular function activating agents for medical purposes; pharmaceutical products for the prevention and treatment of cancer
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79370455
Mark Type
No Service Mark
Attorney Docket Number
No 1166-0298US1
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 12th Nov 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 12th Nov 2024 | REGISTERED-PRINCIPAL REGISTER |
| 09th Nov 2024 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| 23rd Oct 2024 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| 23rd Oct 2024 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| 27th Aug 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 27th Aug 2024 | PUBLISHED FOR OPPOSITION |
| 07th Aug 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 22nd Jul 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 19th Jul 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |